KD PHARMA
LIVE

Serial Number

97376275

Owner

K.D. PHARMA BEXBACH GMBH

Attorney

KLAUS P. STOFFEL

Filing Date

Apr 22, 2022

Add to watchlist:

No watchlists yet
View on USPTO

KD PHARMA Trademark

Serial Number: 97376275 • Registration: 7593034

KD PHARMA is a trademark filed by K.D. PHARMA BEXBACH GMBH on April 22, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 29 (Meats & Processed Foods). The application is currently registered and active.

Owner Contact Info

K.D. PHARMA BEXBACH GMBH (11 trademarks)

AM KRAFTWERK 6
BEXBACH 66450 , DE

Entity Type: 16

Trademark Details

Filing Date

April 22, 2022

Registration Date

December 10, 2024

Published for Opposition

October 8, 2024

Goods & Services

Oils and fats, namely edible oils and edible fats and oils and fats for food; dietetic oils and fats in the nature of edible oils and fats, not for medical purposes; any cannabis or cannabis derived ingredients in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing containing cannabidiol (CBD)

Oils and fats, namely, lipids used in the manufacture of cosmetics, beverages, food products, pharmaceuticals and dietary supplements for the manufacture of pharmaceuticals, medical and veterinary preparations, sanitary preparations for medical purposes, dietetic foodstuffs and products for medical or veterinary purposes, food supplements for humans and animals, medicines and natural remedies, dietetic preparations and food supplements and pharmaceutical preparations and substances, dietary supplements and dietetic preparations, food for babies and infants, and for manufacturing beverages for infants and infant formula; any cannabis or cannabis derived ingredients in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing containing cannabidiol (CBD)

Pharmaceutical, medical and veterinary preparations, namely, pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders, pharmaceutical products for the prevention and treatment of cancer, pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines, and chemical reagents for medical or veterinary purposes, chemical reagents for medical or veterinary purposes; sanitary preparations for medical purposes; dietetic foodstuffs and goods for medical or veterinary purposes, namely, dietetic foods and beverages adapted for medical use, dietetic foods adapted for veterinary use, dietetic beverages adapted for veterinary use, and dietetic preparations adapted for medical purposes; food supplements for humans and animals; disinfectants; medicines and natural remedies, namely medicinal oils and antiallergic medicines, medicinal preparations for the treatment of infectious diseases and for use in oncology, medicinal drinks, medicinal preparations for infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders, for the prevention and treatment of cancer, for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria- based diseases, for the treatment of epilepsy, pain, anxiety, depression, sleep disorders, Parkinson's disease, nausea and vomiting, food disorders, arthritis, PTSD, schizophrenia, opioid addiction, alleviate ALS symptoms, multiple sclerosis, and for the treatment of diabetes, natural remedy preparations for the treatment of gastro-intestinal conditions, hormonal and chemical imbalances, and sleep disorders; dietetic preparations, namely Dietetic preparations adapted for medical purposes; food supplements; food for babies; food for infants; infant formula; any cannabis or cannabis derived ingredients in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing containing cannabidiol (CBD)

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 7, 2026 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jan 7, 2026 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 7, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 7, 2026 REAP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 10, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 10, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 8, 2024 NPUB
PUBLISHED FOR OPPOSITION
Oct 8, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 18, 2024 NONP
EXPARTE APPEAL TERMINATED
Sep 4, 2024 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 4, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 4, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 4, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 4, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 4, 2024 CNEA
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Sep 4, 2024 JURT
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Jul 1, 2024 GNS1
SUBSEQUENT FINAL EMAILED
Jul 1, 2024 GNSF
SUBSEQUENT FINAL REFUSAL WRITTEN
Jul 1, 2024 CFRC
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 4, 2024 ERFR
EX PARTE APPEAL-INSTITUTED
Jun 4, 2024 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Jun 4, 2024 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Jun 4, 2024 EXAF
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Mar 4, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Mar 4, 2024 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 4, 2023 GNFN
FINAL REFUSAL E-MAILED
Dec 4, 2023 GNFR
FINAL REFUSAL WRITTEN
Dec 4, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 21, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 20, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 20, 2023 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 19, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 19, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 20, 2023 GNRN
NON-FINAL ACTION E-MAILED
Mar 20, 2023 GNRT
NON-FINAL ACTION WRITTEN
Mar 20, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 1, 2023 DOCK
ASSIGNED TO EXAMINER
Feb 18, 2023 DOCK
ASSIGNED TO EXAMINER
Feb 9, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 27, 2022 NWOS
NEW APPLICATION ENTERED
Apr 26, 2022 NWAP